PDCD1 and non-small cell lung carcinoma: A prospective, multicenter study has associated a specific epigenetic profile, based on DNA methylation microarrays, with progression‐free survival (PFS) and OS in patients with NSCLC, who were receiving anti‐PD‐1 antibodies.23